By Dr. Margaret Goodman
For years, conversations about performance-enhancing drugs in boxing have focused almost exclusively on the athletes who test positive. Far less attention has been given to what happens after an adverse finding is reported. In this column for The Ring, Dr. Margaret Goodman examines the larger issue: a fragmented system in which commissions, governing bodies, and national anti-doping organizations often handle identical cases in dramatically different ways.
Drawing on her experience as founder and president of VADA, Dr. Goodman discusses the progress that has been made in anti-doping testing, the challenges created by increasingly sensitive laboratory methods, and the need for greater consistency in how results are evaluated and resolved. She argues that protecting clean athletes requires more than sophisticated testing—it requires a fair, transparent, and uniform process for managing the results.
This article originally appeared in The Ring and offers an informed look at one of the most important issues facing modern boxing. We encourage you to read the complete column to better understand why the future of anti-doping depends as much on consistent governance as it does on the science of testing.
Read the full article to learn more about why uniform results management is just as important as drug testing itself.
